Why the study?
Despite several national and international guidelines, the optimal management of patients with asymptomatic carotid stenosis remains controversial.
What are the differences and similarities in recent guidelines regarding the optimal management of patients with asymptomatic carotid stenosis?
What are the differences and similarities in recent guidelines regarding the optimal management of patients with asymptomatic carotid stenosis?
Recent major vascular guidelines consistently recommend best medical therapy for all patients with asymptomatic carotid stenosis, reserving revascularization (CEA or CAS) for specific high-risk subgroups.
Answers are grounded in this paper and cite their sources.
Guideline discrepancies sustain uncertainty in AsxCS management; leaves open need for harmonized recommendations and randomized trials.
Despite the publication of several national/international guidelines, the optimal management of patients with asymptomatic carotid stenosis (AsxCS) remains controversial. This article compares 3 recently released guidelines (the 2020 German-Austrian, the 2021 European Stroke Organization [ESO], and the 2021 Society for Vascular Surgery [SVS] guidelines) vs the 2017 European Society for Vascular Surgery (ESVS) guidelines regarding the optimal management of AsxCS patients.The 2017 ESVS guidelines defined specific imaging/clinical parameters that may identify patient subgroups at high future stroke risk and recommended that carotid endarterectomy (CEA) should or carotid artery stenting (CAS) may be considered for these individuals. The 2020 German-Austrian guidelines provided similar recommendations with the 2017 ESVS Guidelines. The 2021 ESO Guidelines also recommended CEA for AsxCS patients at high risk for stroke on best medical treatment (BMT), but recommended against routine use of CAS in these patients. Finally, the SVS guidelines provided a strong recommendation for CEA+BMT vs BMT alone for low-surgical risk patients with >70% AsxCS. Thus, the ESVS, German-Austrian, and ESO guidelines concurred that all AsxCS patients should receive risk factor modification and BMT, but CEA should or CAS may also be considered for certain AsxCS patient subgroups at high risk for future ipsilateral ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Paraskevas et al. (2022) conducted a review in Asymptomatic carotid stenosis. Carotid endarterectomy (CEA) or carotid artery stenting (CAS) vs. Best medical treatment (BMT) was evaluated. Recent guidelines concur that patients with asymptomatic carotid stenosis should receive best medical treatment, with carotid endarterectomy or stenting considered for high-risk subgroups.
Synapse has enriched 10 related papers. Consider them for comparative context: